분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-08-08 18:06:06 , Hit : 2526
 Urine predicts prostate cancer risk

Published online 3 August 2011 | Nature | doi:10.1038/news.2011.455

News

Test could reduce unnecessary needle biopsies.

Virginia Gewin

A new screening test makes use of urine, rather than blood, to identify the men most at risk of prostate cancer, and may even provide information about how aggressive a tumour is likely to be.

The standard screening test for prostate cancer is a blood test for a protein called prostate specific antigen (PSA). But PSA is also produced by non-cancerous conditions such as enlarged prostates or infection, so is not very specific. "Most men with elevated PSA levels don't have prostate cancer," says Arul Chinnaiyan, director of the Michigan Center for Translational Pathology in Ann Arbor.

Chinnaiyan and his colleagues have developed a new test that detects two markers specific to prostate cancer. One, called TMPRSS2:ERG, is the fusion of two genes, TMPRSS2 and ERG, and is found in around half of prostate tumours found through PSA screening. The other, a non-coding RNA called PCA3, is a very sensitive marker, found in unusually high levels in more than 95% of prostate cancers.

The researchers studied 1,065 men from three academic medical centres and seven community-based hospitals, who had been shown in screening to have elevated PSA. They used their test to stratify the men into low-, intermediate- and high-score groups. Biopsies confirmed cancer in 21% of the low-score group, 43% of the intermediate group and 69% of the high group. The results are published today in Science Translational Medicine1.

Futher studies will allow refinement of the test, but the researchers say patients in the high risk group should definitely get a biopsy. High-scoring men with a negative biopsy might also choose to be closely monitored given their high risk.

Higher urine test scores also correlated with the aggressiveness of the cancer, as determined by the size of the tumour and a standard metric of cell abnormality called the Gleason score. This is something that biopsies cannot do reliably.

The results pave the way for Gen-Probe, the molecular diagnostic company based in San Diego, California, that has licensed the test, to seek approval from the US Food and Drug Administration (FDA).

"This is one big step towards better risk assessment for individual patients," says Jack Schalken, director of research in the urology department at Nijmegen Centre for Molecular Life Sciences in the Netherlands. It is also a significant move towards the goal of personalized medicine, he says, as different subtypes of cancer are likely to require different treatments. "Clinicians are sitting in front of only one person; we need a way to assess how aggressive that patient's cancer is."

Other researchers are cautiously optimistic. Shiv Srivastava, scientific director at the Center for Prostate Disease Research in Rockville, Maryland, says that the study is "a major advance" but that independent studies are needed across races and in more general populations to confirm whether or not the findings extend to all men. The patients in Chinnaiyan's study were mostly white, and Srivastava's recent work suggests that ERG expression is lower in prostate tumours of African American men than in those of caucasian men2.

Biomarker to bedside
Srivastava and Schalken agree, however, that the big advantage of the test over PSA is that it uses markers that are specific to prostate cancer.

Chinnaiyan's team first detected TMPRSS2:ERG in 20053. The finding was surprising because at the time, gene fusions were thought to occur mainly in blood cancers or in rare soft-tissue tumours.

But it makes sense, says Chinnaiyan, because the fusion combines an androgen-regulated gene (TMPRSS2) with a transcription factor (ERG). "Androgen signalling is an important driver of prostate cancer, so it's not surprising that hooking these two genes together can disrupt hormone signalling to the point of causing cancer," he says.

Chinnaiyan's team has discovered more than 25 other gene fusions that are found in smaller percentages of prostate-cancer cases, and hopes that these biomarkers will one day be added to the urine-based test to improve detection rates.

But urine-based tests are not likely to replace the PSA test any time soon. "We are initiating long-term, prospective trials to begin gathering enough data to determine whether this test could, one day, serve as a replacement," says Chinnaiyan. "But the bar will be pretty high when attempting to replace a test physicians have used for so long."

References
Tomlins, S. A. et al. Sci. Transl. Med. 3, 94ra72 (2011).
Rice, K. R. et al. Clin. Cancer Res. 16, 1572-1576 (2010). | Article | PubMed | ISI | ChemPort |
Tomlins, S. A. et al. Science 310, 644-648 (2005). | Article | PubMed | ISI | ChemPort |







727   Treatment of Common Virus Can Reduce Tumour Growth, Study Suggests  이성욱 2011/10/04 2326
726   tRNA 합성효소의 이중기능(dual function)에 대한 미스터리 해명  이성욱 2009/12/18 6329
725   Tufts report confirms domination of biotech products  이성욱 2013/11/19 1865
724   Tumours grow their own blood vessels  이성욱 2010/11/25 2308
723   Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression  이성욱 2016/03/14 718
722   Turning T-cells into Cancer Killers  이성욱 2011/08/12 2532
721   U of M researchers discover gene required to maintain male sex throughout life  이성욱 2011/07/25 2282
720   U. Iowa team investigates function of 'junk DNA' in human genes  이성욱 2011/03/04 2209
719   UCD stem cell research battles Huntington's disease  이성욱 2012/02/01 2511
718   UK Duo Generates Haploid Mouse Stem Cells  이성욱 2011/09/14 2416
717   Un-junking junk DNA  이성욱 2013/11/15 1855
716   Uncovering a Key Player in Metastasis  이성욱 2011/11/21 2572
715   Uncovering Functions of Circular RNAs  이성욱 2017/08/14 743
714   Understanding HIV Latency to Undo It  이성욱 2011/05/23 2454
713   Unexpected Find Opens Up New Front in Effort to Stop HIV  이성욱 2011/01/31 2118
712   UPDATE 1-Merck says FDA turns down Gardasil for older women  이성욱 2011/04/08 4384
711   UPDATE 1-Vertex drug promising in hep C patients with HIV  이성욱 2011/03/04 2615
710   UPDATE 2-Gilead experimental drug fights all forms of hep C: data  이성욱 2015/09/24 844
709   UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis  이성욱 2017/08/31 712
  Urine predicts prostate cancer risk  이성욱 2011/08/08 2526

[이전 10개] [1]..[21][22][23][24][25][26][27] 28 [29][30]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN